Translating biology into clinic: the case of glioblastoma

Current Opinion in Cell Biology

Volumn 21, Issue 2, 2009, Pages 311-316

  Lino, Maddalena ^a   Merlo, Adrian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TEMOZOLOMIDE;

APOPTOSIS; CANCER INVASION; CELL DIFFERENTIATION; DNA METHYLATION; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GLIOBLASTOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION;

EID: 63749125730     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2008.12.009     Document Type: Review

References (48)

1. Newton H.B. Primary brain tumors: review of etiology, diagnosis and treatment. Am Fam Physician 49 (1994) 787-797
2. Davis F.G., and McCarthy B.J. Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther 1 (2001) 395-401
3. Newton H.B. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4 (2004) 105-128. This is a complete review on the molecular aspects and development of targeted therapeutic strategies in brain tumor.
4. Schneider S.W., Ludwig T., Tatenhorst L., Braune S., Oberleithner H., Senner V., and Paulus W. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 107 (2004) 272-276
5. Merlo A., Hausmann O., Wasner M., Steiner P., Otte A., Jermann E., Freitag P., Reubi J.C., Muller-Brand J., Gratzl O., et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5 (1999) 1025-1033
6. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., and Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7 (2005) 134-153
7. Merlo A., Mueller-Brand J., and Maecke H.R. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl 88 (2003) 83-91
8. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., and Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 8 (2007) 610-622
9. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
10. Knobbe C.B., Merlo A., and Reifenberger G. Pten signaling in gliomas. Neuro-oncol 4 (2002) 196-211
11. Hunter C., Smith R., Cahill D.P., Stephens P., Stevens C., Teague J., Greenman C., Edkins S., Bignell G., Davies H., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66 (2006) 3987-3991
12. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
13. Mehrian-Shai R., Chen C.D., Shi T., Horvath S., Nelson S.F., Reichardt J.K., and Sawyers C.L. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 104 (2007) 5563-5568
14. Kao G.D., Jiang Z., Fernandes A.M., Gupta A.K., and Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282 (2007) 21206-21212
15. Stegh A.H., Kim H., Bachoo R.M., Forloney K.L., Zhang J., Schulze H., Park K., Hannon G.J., Yuan J., Louis D.N., et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21 (2007) 98-111
16. Huang P.H., Cavenee W.K., Furnari F.B., and White F.M. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle 6 (2007) 2750-2754
17. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., Dimeco F., and Vescovi A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444 (2006) 761-765
18. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., and Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
19. Radtke F., and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat Rev Cancer 3 (2003) 756-767
20. Boulay J.L., Miserez A.R., Zweifel C., Sivasankaran B., Kana V., Ghaffari A., Luyken C., Sabel M., Zerrouqi A., Wasner M., et al. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2 (2007) e576. The paper nicely shows that combined assessment of NOTCH2 genetic markers predicts survival with an accuracy that is equivalent to histological classification and higher than current genetic evaluation by 1p/19q LOH. NOTCH2 (N2/N2N) new molecular test described in the paper is a powerful method to detect prognostically favorable gliomas.
21. Mohile N.A., Forsyth P., Stewart D., Raizer J.J., Paleologos N., Kewalramani T., Louis D.N., Cairncross J.G., and Abrey L.E. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol 89 (2008) 187-193
22. Ma L., and Weinberg R.A. MicroRNAs in malignant progression. Cell Cycle 7 (2008) 570-572
23. Ciafre S.A., Galardi S., Mangiola A., Ferracin M., Liu C.G., Sabatino G., Negrini M., Maira G., Croce C.M., and Farace M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334 (2005) 1351-1358
24. Chan J.A., Krichevsky A.M., and Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65 (2005) 6029-6033
25. Gillies J.K., and Lorimer I.A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6 (2007) 2005-2009
26. Papagiannakopoulos T., Shapiro A., and Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68 (2008) 8164-8172
27. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39 (2007) 237-242
28. Martini M., Pallini R., Luongo G., Cenci T., Lucantoni C., and Larocca L.M. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer (2008)
29. Zhou H., Miki R., Eeva M., Fike F.M., Seligson D., Yang L., Yoshimura A., Teitell M.A., Jamieson C.A., and Cacalano N.A. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res 13 (2007) 2344-2353
30. Tepel M., Roerig P., Wolter M., Gutmann D.H., Perry A., Reifenberger G., and Riemenschneider M.J. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123 (2008) 2080-2086
31. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., and Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
32. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., et al. Long-term survival with glioblastoma multiforme. Brain 130 (2007) 2596-2606
33. Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., Mehta M.P., and Gilbert M.R. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26 (2008) 4189-4199
34. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006) 157-173. This paper shows that chromosomal locations of genes distinguishing tumor subclass parallel DNA copy number differences between subclasses. A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively.
35. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., and Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40 (2008) 499-507
36. Bachoo R.M., Maher E.A., Ligon K.L., Sharpless N.E., Chan S.S., You M.J., Tang Y., DeFrances J., Stover E., Weissleder R., et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1 (2002) 269-277. This paper showed that transduction of Ink4a/Arf(-/-) neural stem cells (NSCs) or astrocytes with constitutively active EGFR induces a common high-grade glioma phenotype. Both NSCs and astrocytes are equally permissive compartments for gliomagenesis and provide evidence that p16(INK4a) and p19(ARF) synergize to maintain terminal astrocyte differentiation.
37. Karnoub A.E., and Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9 (2008) 517-531
38. Merlo A. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 26 (2003) 145-158
39. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., Griffin J.D., and Kwiatkowski D.J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117 (2007) 730-738
40. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006) 1500-1508
41. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118 (2008) 3065-3074. They show that pharmacological inhibition of the MAPK pathway enhanced the antitumoral effect of mTORC1 inhibition by rapamycin in cancer cells. These findings identify MAPK activation as a consequence of mTORC1 inhibition and underscore the potential of a combined therapeutic approach with mTORC1 and MAPK inhibitors for the treatment of human cancers.
42. Walker M.D., Green S.B., Byar D.P., Alexander Jr. E., Batzdorf U., Brooks W.H., Hunt W.E., MacCarty C.S., Mahaley Jr. M.S., Mealey Jr. J., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 (1980) 1323-1329
43. Failly M., Korur S., Egler V., Boulay J.L., Lino M.M., Imber R., and Merlo A. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 6 (2007) 773-781
44. Sathornsumetee S., Reardon D.A., Desjardins A., Quinn J.A., Vredenburgh J.J., and Rich J.N. Molecularly targeted therapy for malignant glioma. Cancer 110 (2007) 13-24
45. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
46. Egler V., Korur S., Failly M., Boulay J.L., Imber R., Lino M.M., and Merlo A. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 14 (2008) 3132-3140. This paper shows that simultaneous blockade of histone deacetylation and glycolysis induces strong apoptosis in cancer cell lines of brain, breast, and cervix in a p53-independent manner. This approach represents a novel therapeutic strategy for several major cancers.
47. Kneifel S., Cordier D., Good S., Ionescu M.C., Ghaffari A., Hofer S., Kretzschmar M., Tolnay M., Apostolidis C., Waser B., et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 12 (2006) 3843-3850
48. Zalutsky M.R., Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., McLendon R.E., Wong T.Z., and Bigner D.D. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49 (2008) 30-38